Jonas Ecker
144 works · 2,057 citations · h-index 22
Top works
- Sarcoma classification by DNA methylation profiling
- Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions
- Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations
- The molecular landscape of ETMR at diagnosis and relapse
- Response to trametinib treatment in progressive pediatric low-grade glioma patients
- PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum
- Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification
- Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B
- Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas
- Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
- The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma
- Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions
- Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing
- Advancing CNS tumor diagnostics with expanded DNA methylation-based classification
- Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma
- Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors
- Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma
- Targeting of histone deacetylases in brain tumors
- GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types
- Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma